98516-10-0Relevant articles and documents
TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS
-
Paragraph 0081; 0084; 0086, (2021/09/26)
Compounds of formula (I), pharmaceutical compositions comprising compounds of the formula (I), and methods of treating an HIV infection comprising administering an effective amount of one or more compounds of formula (I), or a pharmaceutical composition comprising same.
An enantioselective enzymatic desymmetrization route to hexahydro-4H-furopyranol, a high-affinity ligand for HIV-1 protease inhibitors
Ghosh, Arun K.,Sarkar, Anindya
supporting information, p. 3230 - 3233 (2017/07/27)
An enantioselective synthesis of (3aS,4S,7aR)-hexahydro-4H-furo[2,3-b]pyran-4-ol, a high-affinity nonpeptide ligand for a variety of potent HIV-1 protease inhibitors is described. The key steps involved a highly enantioselective enzymatic desymmetrization
Access to the akuammiline family of alkaloids: Total synthesis of (+)-scholarisine A
Adams, Gregory L.,Carroll, Patrick J.,Smith, Amos B.
supporting information, p. 519 - 528 (2013/02/25)
The planning and implementation of an enantioselective total synthesis of (+)-scholarisine A is presented. Key tactics employed include a novel cyclization, consisting of a nitrile reduction coupled with concomitant addition of the resultant amine to an epoxide; a modified Fischer indolization; an oxidative lactonization of a diol in the presence of an indole ring; and a late-stage cyclization to complete the caged ring scaffold. The development of a possible "retro-biosynthetic" approach to other members of the akuammiline alkaloid family is also described.